Unknown

Dataset Information

0

Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia.


ABSTRACT: Anti-CD20 antibody therapy has been a useful medication for managing non-Hodgkin's lymphoma as well as autoimmune diseases characterized by autoantibody generation. CD20 is expressed during most developmental stages of B lymphocytes; thus, CD20 depletion leads to B-lymphocyte deficiency. As the drug has become more widely used, there has been an increase in the number of case reports of patients developing Pneumocystis pneumonia. The role of anti-CD20 in Pneumocystis jirovecii infection is under debate due to the fact that most patients receiving it are on a regimen of multiple immunosuppressive medications. To address the specific role of CD20 depletion in host immunity against Pneumocystis, we examined a murine anti-CD20 depleting antibody. We demonstrated that anti-CD20 alone is permissive for Pneumocystis infection and that anti-CD20 impairs components of type II immunity, such as production of interleukin-4 (IL-4), IL-5, and IL-13 by whole-lung cells, in response to Pneumocystis murina. We also demonstrated that CD4(+) T cells from mice treated with anti-CD20 during Pneumocystis infection are incapable of mounting a protective immune response when transferred into Rag1(-/-) mice. Thus, CD20(+) cells are critical for generating protective CD4(+) T-cell immune responses against this organism.

SUBMITTER: Elsegeiny W 

PROVIDER: S-EPMC4399075 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia.

Elsegeiny Waleed W   Eddens Taylor T   Chen Kong K   Kolls Jay K JK  

Infection and immunity 20150302 5


Anti-CD20 antibody therapy has been a useful medication for managing non-Hodgkin's lymphoma as well as autoimmune diseases characterized by autoantibody generation. CD20 is expressed during most developmental stages of B lymphocytes; thus, CD20 depletion leads to B-lymphocyte deficiency. As the drug has become more widely used, there has been an increase in the number of case reports of patients developing Pneumocystis pneumonia. The role of anti-CD20 in Pneumocystis jirovecii infection is under  ...[more]

Similar Datasets

| S-EPMC10647007 | biostudies-literature
| S-EPMC5364303 | biostudies-literature
2019-08-14 | E-MTAB-7473 | biostudies-arrayexpress
| S-EPMC5311060 | biostudies-literature
| S-EPMC6686957 | biostudies-literature
| S-EPMC5369497 | biostudies-other
| S-EPMC6123398 | biostudies-literature
| S-EPMC9037831 | biostudies-literature
| S-EPMC3099572 | biostudies-literature
| S-EPMC3754224 | biostudies-literature